Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib

Inclusion Criteria

• Subjects must provide written informed consent prior to performance of study specific procedures or assessments, and must be willing to comply with treatment and follow up.
• Procedures conducted as a part of routine clinical management of the subject (e.g., blood count, imaging study) and obtained prior to signed informed consent may be utilized for Screening or Baseline purposes provided these tests are obtained as specified in the protocol).
• Subjects must have measurable or evaluable disease. Disease sites that are evaluable for progression but not measurable per RECIST guidelines include:
• Bone lesions
• Previously irradiated lesions
• Cutaneous manifestations (non-discreet lesions only)
• Age ≥ 18 years.
• Postmenopausal women defined by one of the criteria:
• No spontaneous menses for at least 12 months if the subject is ≥ 50 years old;
• Amenorrheic for at least 12 months if the subject is 480msecs.
• History of any one or more of the following cardiovascular conditions within the past 6 months:
• Angioplasty or stenting
• Myocardial infarction
• Unstable angina
• Coronary artery by-pass graft surgery
• Symptomatic peripheral vascular disease
• Class II, III or IV congestive heart failure, as defined by the New York Heart Association (NYHA).
• Use of an investigational agent, including an investigational anti-cancer agent, within 14 days prior to the first dose of study drug.
• Prior use of an investigational drug that targets VEGF or VEGF receptors.
• Any ongoing toxicity from prior anti-cancer therapy that is > Grade 1 and/or that is progressing in severity.
• Poorly controlled hypertension (defined as systolic blood pressure (SBP) of ≥140mmHg or diastolic blood pressure (DBP) of ≥ 90mmHg).

Note: Initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry. Blood pressure must be re-assessed prior to start of study therapy. The mean SBP/DBP values must be <140/90mmHg (OR 150/90mmHg, if this criterion is approved by Safety Review Team) in order for a subject to be eligible for the study.

• History of cerebrovascular accident (CVA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months.

Note: Subjects with recent DVT who have been treated with therapeutic anti-coagulant agents for at least 6 weeks are eligible.

• Major surgery or trauma within 28 days prior to first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer not related to cancer (procedures such as catheter placement not considered to be major).
• Evidence of active bleeding or bleeding diathesis.
• Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance to study procedures